Xconomy | Boston - Business + Technology in the Exponential Economy

Pharmas Flock to Sermo, Biogen Idec Takes Another Tack with MS, $400M More for the Broad Institute, & More Life Sciences News
Rod Brooks Follows His Heart(land), Amazon Helps Out OLPC, the Broad Gets $400M, GT Solar Shines Over Big Contract, & More Deals News
Hepregen Inc. Garners $3,000,000 Series A Round
Venture Rounds at Energetiq, ExtendMedia, Viridity
.406 Ventures Caps First Fund at $167 Million; Focused on Massachusetts IT Firms

Hepregen Raises $3 Million To Screen Drugs for Liver Damage

Hepregen, an MIT spinoff company developing a way to screen drugs in development for liver toxicity, has raised $3 million out of a $5 million first round of venture capital, according to a regulatory filing cited by Private Equity Hub. The backers of the company include Battelle Ventures and Innovation Valley Partners. Sangeeta Bhatia and Salman Khetani founded the company, according to this article in Technology Review.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: